此内容来自:xinyabo体育

奇尔顿的vivus赌注泉水

    By Pete Gallo One of the most spectacular payoffs in public stocks so far this year has been Chilton Investment Co.’s incorrigible portfolio bet on a smaller-cap pharmaceutical specialist called Vivus, whose share-price trajectory has surged from burgeoning to ballistic, thanks to recent regulatory approvals for its experimental weight-loss drug,

    继续阅读,现在订阅高级新闻。已经订阅了订阅者?登录